VLP Therapeutics, Inc. is pioneering innovative vaccine technologies, particularly through its i-αVLP (inserted alphavirus virus-like particle) platform. This platform is designed to deliver a high density of antigens on the surface of virus-like particles, which are structurally similar to native viruses but lack genetic material, making them non-replicative and safe for use. The i-αVLP technology has shown promise in inducing strong immune responses, as evidenced by its application in developing a malaria vaccine currently in Phase I/IIa trials. Additionally, the platform has demonstrated potential in targeting immune checkpoint inhibitors, which could enhance cancer treatment strategies.

The company is also advancing its efforts in infectious disease vaccines, including a tetravalent dengue vaccine and a self-amplifying RNA vaccine for SARS-CoV-2. The dengue vaccine has shown the ability to induce antibodies and reduce viral replication in preclinical studies involving monkeys. Meanwhile, the self-amplifying RNA vaccine, VLPCOV-02, has reported positive safety and immunogenicity results, and a Phase 3 clinical trial for a COVID-19 booster targeting the Omicron variant is underway. These developments highlight VLP Therapeutics' commitment to addressing significant public health challenges through next-generation vaccine technologies.

United States

VLP Therapeutics, Inc. (VLPT) was established in 2013 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology. The company is headquartered in Gaithersburg, Maryland.

VLP Therapeutics, Inc.

Company Details